Study of Nerivio in adolescents with migraine published in Headache journal.- Theranica

Theranica announced that a new peer-reviewed study demonstrates the potential of remote electrical neuromodulation (REN) for the acute treatment of migraine in adolescents. The study used Theranica's Nerivio therapeutic wearable, currently FDA-cleared for adult patients, and demonstrates that adolescents may also benefit from using the device. Nerivio is currently under review by the FDA for indication expansion to adolescents. The study, published in Headache, the official peer-reviewed journal of the American Headache Society, evaluated 45 episodic and chronic migraine patients between the ages of 12 and 17, who completed at least one treatment with Nerivio. 159 migraine headaches were treated with the device over the course of the study, mostly moderate (49%) or severe (33%) at baseline. At two hours after treatment, 71% of participants reported pain relief and 35% reported pain freedom. Pain relief and pain freedom were sustained for 24 hours in 90% of cases. 69% of patients experienced improvement in functional ability, defined by ability to do schoolwork and perform "usual activities," at two hours. There were no device-related serious adverse events. The study also assessed effectivity of Nerivio through the Pediatric Migraine Disability Assessment questionnaire, which asked patients how migraine interfered with school and daily activities. The average decrease in the scores observed (from 37.1 to 18.6) indicates a reduction from moderate to mild disability. See: "Remote electrical neuromodulation for acute treatment of migraine in adolescents." Andrew D. Hershey et al. Headache 21 December 2020 https://doi.org/10.1111/head.14042